Back to Search
Start Over
Ganstigmine. Chiesi.
- Source :
-
Current opinion in investigational drugs (London, England : 2000) [Curr Opin Investig Drugs] 2003 Jul; Vol. 4 (7), pp. 868-73. - Publication Year :
- 2003
-
Abstract
- Ganstigmine (CHF-2819) is being developed by Chiesi as a potential treatment for neurodegenerative and cognitive disorders. The drug was in phase IIa studies in the US for senile dementia associated with Alzheimer's disease (AD) by mid-2000, and phase IIb trials in AD patients were scheduled for early 2001, with these ongoing in 2002.
- Subjects :
- Alkaloids chemistry
Alzheimer Disease psychology
Animals
Carbamates chemistry
Clinical Trials as Topic statistics & numerical data
Drugs, Investigational chemistry
Humans
Technology, Pharmaceutical methods
Alkaloids therapeutic use
Alzheimer Disease drug therapy
Carbamates therapeutic use
Drugs, Investigational therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1472-4472
- Volume :
- 4
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Current opinion in investigational drugs (London, England : 2000)
- Publication Type :
- Academic Journal
- Accession number :
- 14619410